FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to modulating the amount of hepcidin, and can be applied in medicine for treatment of diseases associated with the metabolism of iron in a subject. This method of treatment involves administering to a subject a composition comprising (I) an antibody that specifically recognizes an erythroferrone polypeptide or a fragment thereof, and (II) a pharmaceutically acceptable carrier or diluent.
EFFECT: invention is effective in hemochromatosis or disorders associated with abnormally low levels of hepcidin.
4 cl, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF | 2014 |
|
RU2668391C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| PROTEINS BINDING TO HEPCIDIN | 2011 |
|
RU2625011C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| DISEASE DIAGNOSTICS TECHNIQUE BY ORGANISM TISSUES, BLOOD OR LIQUIDS SCREENING IN ANIMAL OR HUMAN FOR NONPHYSIOLOGICAL HEPSIDIN LEVELS AND ITS THERAPEUTIC APPLICATION | 2003 |
|
RU2359268C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
| FACTOR EFFECTING ON ACTIVITY OF TUMOR NECROSIS FACTOR RECEPTOR-RELEASING ENZYME | 1999 |
|
RU2279478C2 |
| ANTIBODIES SPECIFIC TO TUMOUR AND USE THEREOF | 2011 |
|
RU2595403C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
